IRLAB Therapeutics AB publishes annual report for 2018
IRLAB announced today that the company’s annual report for 2018 is available on the company website, www.irlab.se/investor-relations/financial-reports/.
The report is originally published in Swedish and will be available in English.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
FNCA Sweden AB, +46 8 528 00 399; email@example.com, is the company's Certified Adviser on Nasdaq First North Premier.
IRLAB is a Swedish biotech company focused on Parkinson's disease. The company's clinical Phase II candidates, IRL752 and IRL790, intend to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (LIDs), psychosis and dementia. Through the proprietary ISP (Integrative Screening Process) research platform, IRLAB discovers and develops drug candidates for central nervous system (CNS) related diseases where big growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, firstname.lastname@example.org, +46 (0)8‑528 00 399. More information on www.irlab.se.